Literature DB >> 17254844

Increased circulating concentrations and augmented myocardial extraction of osteoprotegerin in heart failure due to left ventricular pressure overload.

Satu Helske1, Petri T Kovanen, Ken A Lindstedt, Kaija Salmela, Jyri Lommi, Heikki Turto, Kalervo Werkkala, Markku Kupari.   

Abstract

BACKGROUND: Osteoprotegerin (OPG) and the receptor activator of nuclear factor-kappaB ligand (RANKL), two cytokines regulating bone remodeling, have recently been raised as potential pathogenetic factors in cardiovascular diseases. We have studied circulating and myocardial OPG and RANKL in patients having severe aortic stenosis (AS) with or without heart failure (HF).
METHODS: We studied 131 adults with AS. Blood was sampled from the aortic root, coronary sinus, and femoral vein at cardiac catheterization. LV myocardial biopsies were taken at surgery. Plasma OPG and soluble (s)RANKL were analyzed by ELISA, and myocardial OPG and RANKL by RT-PCR and immunohistochemistry.
RESULTS: Circulating OPG was elevated in AS patients with HF, the association being independent of age, sex, and presence of coronary artery disease (beta=0.17, p=0.033). Elevated plasma OPG decreased after valve replacement in patients with preoperative HF (p=0.0005). Relative to its concentration in the aortic root, plasma OPG was reduced in the coronary sinus (p<0.05) and in the femoral vein (p<0.001), these arteriovenous gradients being accentuated in HF (p=0.003).
CONCLUSIONS: HF due to LV pressure overload in AS increases circulating OPG and augments OPG extraction by the heart and peripheral tissues. OPG may be involved in the pathogenesis of HF and could serve as a useful biomarker in HF due to LV pressure overload.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17254844     DOI: 10.1016/j.ejheart.2006.10.015

Source DB:  PubMed          Journal:  Eur J Heart Fail        ISSN: 1388-9842            Impact factor:   15.534


  14 in total

1.  Association of serum osteoprotegerin with left ventricular mass in African American adults with hypertension.

Authors:  Amit Noheria; Thomas H Mosley; Iftikhar J Kullo
Journal:  Am J Hypertens       Date:  2010-03-25       Impact factor: 2.689

2.  Amlodipine and atorvastatin improved hypertensive cardiac hypertrophy through regulation of receptor activator of nuclear factor kappa B ligand/receptor activator of nuclear factor kappa B/osteoprotegerin system in spontaneous hypertension rats.

Authors:  Jingchao Lu; Fan Liu; Demin Liu; Hong Du; Jie Hao; Xiuchun Yang; Wei Cui
Journal:  Exp Biol Med (Maywood)       Date:  2016-02-22

3.  Biomarkers of left ventricular hypertrophy and remodeling in blacks.

Authors:  Thais Coutinho; Malik Al-Omari; Thomas H Mosley; Iftikhar J Kullo
Journal:  Hypertension       Date:  2011-10-10       Impact factor: 10.190

4.  Plasma osteoprotegerin, its correlates, and risk of heart failure: a prospective cohort study.

Authors:  Romina di Giuseppe; Ronald Biemann; Janine Wirth; Juliane Menzel; Berend Isermann; Gabriele I Stangl; Andreas Fritsche; Heiner Boeing; Matthias B Schulze; Cornelia Weikert
Journal:  Eur J Epidemiol       Date:  2016-06-15       Impact factor: 8.082

5.  Relationship between RANKL and neuroendocrine activation in elderly males with heart failure.

Authors:  Goran Loncar; Biljana Bozic; Vojkan Cvorovic; Zoran Radojicic; Sinisa Dimkovic; Natasa Markovic; Nenad Prodanovic; Toplica Lepic; Biljana Putnikovic; Vera Popovic-Brkic
Journal:  Endocrine       Date:  2009-11-20       Impact factor: 3.633

6.  TNF-alpha modulates the migratory response of mesenchymal stem cells to TRAIL.

Authors:  Federica Corallini; Paola Secchiero; Antonio Paolo Beltrami; Daniela Cesselli; Elisa Puppato; Roberto Ferrari; Carlo Alberto Beltrami; Giorgio Zauli
Journal:  Cell Mol Life Sci       Date:  2010-01-09       Impact factor: 9.261

7.  RANKL Expression Is Increased in Circulating Mononuclear Cells of Patients with Calcific Aortic Stenosis.

Authors:  Marcello Rattazzi; Elisabetta Faggin; Elisa Bertacco; Roberta Buso; Massimo Puato; Mario Plebani; Martina Zaninotto; Davide Condotta; Giacomo Zoppellaro; Leopoldo Pagliani; Giuseppe Tarantini; Sabino Iliceto; Elisa Covolo; Giuseppe Faggian; Francesco Onorati; Mikhail Dodonov; Alessandro Daniotti; Paola Pantano; Zoran Olivari; Giovanni Benfari; Paolo Pauletto
Journal:  J Cardiovasc Transl Res       Date:  2018-05-17       Impact factor: 4.132

Review 8.  Osteoprotegerin, vascular calcification and atherosclerosis.

Authors:  Ann Van Campenhout; Jonathan Golledge
Journal:  Atherosclerosis       Date:  2008-10-09       Impact factor: 5.162

9.  Serum Osteoprotegerin and Carotid Intima-Media Thickness Are Related to High Arterial Stiffness in Heart Failure with Reduced Ejection Fraction.

Authors:  Lajos Fehérvári; Attila Frigy; Lóránd Kocsis; István Adorján Szabó; Timea Magdolna Szabo; Melinda Urkon; Zita Jakó; Előd Ernő Nagy
Journal:  Diagnostics (Basel)       Date:  2021-04-24

10.  Osteoprotegerin as a marker of atherosclerosis in diabetic patients.

Authors:  Areti Augoulea; Nikolaos Vrachnis; Irene Lambrinoudaki; Konstantinos Dafopoulos; Zoe Iliodromiti; Angelos Daniilidis; Michail Varras; Andreas Alexandrou; Efthymios Deligeoroglou; George Creatsas
Journal:  Int J Endocrinol       Date:  2013-01-17       Impact factor: 3.257

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.